We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)

This study is not yet open for participant recruitment.
Verified November 2017 by University of Arkansas
Sponsor:
ClinicalTrials.gov Identifier:
NCT03003728
First Posted: December 28, 2016
Last Update Posted: November 20, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborators:
Bristol-Myers Squibb
Altor BioScience
Information provided by (Responsible Party):
University of Arkansas
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is not yet open for participant recruitment.
  Estimated Study Completion Date: August 2019
  Estimated Primary Completion Date: August 2019 (Final data collection date for primary outcome measure)